Skip to main content

COVID-19 Advisory: If you have a fever or cold like symptoms, call us before visiting our clinics or emergency department. Only one primary caregiver may accompany a patient at all locations. No other visitors allowed. For more information visit our COVID-19 Resource Center.

Histiocytosis Program

Histiocytosis, often referred to as the “orphan disease,” is a rare blood disease that affects only about 1 in 200,000 children born each year in the US. 


We have Arizona’s only histiocytosis team exclusively focused on the disease.

Our team benefits from working with the vast resources available to Phoenix Children’s and our Center for Cancer and Blood Disorders. This opportunity ensures our patients, and their loved ones, understand and benefit from the care and treatment journey.

A hallmark of histiocytosis is abnormal cell growth, but not necessarily cancerous growth. These cells are often found in the immune system and can manifest as Langerhans Cell Histiocytosis (LCH), Hemophagocytic Lymphohistiocytosis (HLH), Juvenile Xanthogranulomatosis (JXG) and Rosai-Dorfman Disease (RDD), among others.

Additional Resources

  • Research/Clinical Trials — Did you know there are currently more than 70 open clinical trials available for cancer patients at Phoenix Children's? 
  • Want a Second Opinion? — Chat, call, or complete this form to request a second opinion appointment.
  • Your Child's Hospital Stay — Learn more about our campus services and what you can do to prepare for your visit.

 


Share this page